PolyPid Ltd. POLY 深 滬
等待開盤 10-28 09:30:00 美东时间
39.82
0.000
0.00%
華盛通- 最 高--
- 今 開--
- 成交量 0股
- 最 低 --
- 昨 收 39.82
- 總市值 175.18万
- 52周最高 40.82
- 市盈率 靜 97.67
- 換手率 0.00%
- 52周最低 22.69
- 委 比 0.00%
- 總股本 4.40万
- 歷史最高 81.23
- 量 比 0
- 振 幅 0.00%
- 歷史最低 4.60
- 每 手 1
- 風險率 0.00%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多This PPL Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. BTIG analyst David Larsen initiated coverage on DarioHealth Corp (NASDAQ:DRIO) with a Buy rating ...
10-27 20:08
PolyPid to Present D-PLEX₁₀₀ Microbiology Data at IDWeek 2026
PolyPid Ltd. announced at IDWeek 2026 that its D-PLEX₁₀₀ treatment showed lower bacterial burden and delayed onset of surgical-site infections (SSIs) compared to standard care, without increasing multidrug-resistant organisms. The exploratory analysis from 2,185 patients across three trials highlighted a 60% relative risk reduction in SSIs and favorable microbiological outcomes, supporting its potential in combating antimicrobial resistance.
10-21 12:00
PolyPid to Report Second Quarter 2026 Financial Results and Operational Highlights on August 12, 2026
PolyPid Ltd. (Nasdaq: PYPD) announced it will report its Q2 2026 financial results and operational highlights before the U.S. market open on August 12, 2026. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide a business update. Registration is recommended 5 minutes prior to the call. For more information, visit PolyPid's website or contact investor relations.
07-30 12:00
PolyPid rises as lead product granted FDA priority review
PolyPid (PYPD) added more than 7% on Wednesday after the Israeli biopharma received the FDA's priority review for a marketing application seeking U.S. approval for its lead product candidate D-PLEX100...
07-30 02:20
PolyPid Signs Agreement With Azurity Pharmaceuticals To Commercialize D-PLEX100 In U.S., Canada To Prevent Surgical Site Infections; PolyPid To Receive $15M Upfront Payment
PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), an innovative biopharmaceutical company dedicated to elevating treatment effectiveness, right where care begins, today announced that it has entered into an exclusive commercial partnership agreement (the "Agreement") with Azurity Pharmaceutic...
07-21 19:32
PolyPid Completes Its New Drug Application Submission On Rolling Review Basis Top FDA For D-PLEX100 To Prevent Surgical Site Infections
PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), an innovative biopharmaceutical company dedicated to improving patient outcomes by elevating treatment effectiveness, right where care begins, today announced the
06-01 20:40
PolyPid to Report First Quarter 2026 Financial Results and Operational Highlights on May 13, 2026
PolyPid Ltd. (Nasdaq: PYPD) announced it will report its first quarter 2026 financial results and operational highlights on Wednesday, May 13, 2026, before the U.S. market open. A conference call and webcast at 8:30 AM Eastern Time will discuss the results and business updates. The company, focused on improving patient outcomes through innovative biopharmaceuticals, invites participants to register in advance for the call or listen via webcast.
05-06 12:00
PolyPid To Present ASEPSIS Analysis Data From Its Phase 3 SHIELD II Study Of D-PLEX At 5th Annual Meeting Of The Surgical Infection Society
PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), an innovative biopharmaceutical company dedicated to improving patient outcomes by elevating treatment effectiveness, right where care begins, today announced that
04-28 20:37
PolyPid To Present Phase 3 SHIELD II Data Showing Sustained Local Doxycycline Release And Minimal Systemic Exposure At ESCMID 2026 Conference
PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), an innovative biopharmaceutical company dedicated to improving patient outcomes by elevating treatment effectiveness, right where care begins, today announced that
04-13 21:16
PolyPid Initiates D-PLEX₁₀₀ NDA Submission to the FDA
PolyPid Ltd. has initiated the submission of its New Drug Application (NDA) to the FDA for D-PLEX₁₀₀, aimed at preventing surgical site infections (SSIs) in colorectal surgery patients. The submission, under the FDA’s Fast Track designation, includes the Chemistry, Manufacturing and Controls (CMC) and nonclinical sections, with the clinical section expected in the second quarter of 2026. D-PLEX₁₀₀, which uses PolyPid’s Kynatrix technology, provid...
03-31 12:30
